Pediatric Allergy/Immunology & Rheumatology Research
BLU Trial
This study is currently closed to enrollment.
Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy
AGE: 18+ years old
SEX AT BIRTH: All
SEX AT BIRTH: All
TYPE: Interventional Study
HEALTHY PARTICIPANTS: No
HEALTHY PARTICIPANTS: No
CONDITION: Systemic Mastocytosis (SM) and Indolent
LOCATION: University Hospitals Rainbow Babies & Children’s
LOCATION: University Hospitals Rainbow Babies & Children’s
Study Purpose
The purpose of this study is to learn more about the safety and effectiveness of an experimental drug called avapritinib (formerly called BLU285), when given to individuals who have been diagnosed with ISM.